Cascadian Therapeutics
Nov 15, 2016
PDF

Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the 2016 San Antonio Breast Cancer Symposium

Updated "Triplet" data to be presented at SABCS

SEATTLE, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company's lead product candidate tucatinib (also known as ONT-380) will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) to be held December 6-10 in San Antonio, TX.

The Phase 1b "Triplet" poster presentation will include more mature progression-free survival (PFS) and safety data not included in the abstract posted on the SABCS website, which was as of May 2016.

Details of Poster Presentations:

A Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine (C) and Trastuzumab (T) in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (MBC) (HER2CLIMB)
First Author:  Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session:  OT1-02-09, Ongoing Trials — Chemotherapy
Date/Time:  Wednesday, December 7, 2016; 5:00 p.m.—7:00 p.m. CST

Efficacy Results of a Phase 1b Study of ONT-380, an Oral HER2-Specific Inhibitor, in Combination with Capecitabine (C) and Trastuzumab (T) in HER2+ Metastatic Breast Cancer (MBC), Including Patients (pts) with Brain Metastases (mets)
First Author:  Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session:  P4-21-01, Treatment: HER2-Targeted Therapy
Date/Time:  Friday, December 9, 2016; 7:30 a.m.—9:00 a.m. CST

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, also known as ONT-380, is an oral, selective small molecule HER2 inhibitor. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information and to sign up for email alerts or RSS feeds, please visit www.cascadianrx.com.

Contacts:

Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com

Media:
Brad Miles
BMC Communications
917-570-7340
bmiles@bmccommunications.com